Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upadacitinib - AbbVie

Drug Profile

Upadacitinib - AbbVie

Alternative Names: ABT-494; RINVOQ; Upadacitinib extended release - Abbvie; Upadacitinib modified release - Abbvie; Upadacitinib prolonged release - Abbvie; Upadacitinib tartrate; Upadicitinib hemihydrate - Abbvie

Latest Information Update: 26 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase III Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Giant cell arteritis; Psoriatic arthritis; Ulcerative colitis; Vasculitis
  • Phase II Systemic lupus erythematosus
  • Phase I Juvenile rheumatoid arthritis

Most Recent Events

  • 07 Feb 2020 Abbvie announces intention to submit regulatory applications for Psoriatic arthritis in the second quarter of 2020
  • 06 Feb 2020 Launched for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in United Kingdom (PO, Controlled release), before February 2020
  • 06 Feb 2020 Launched for Rheumatoid arthritis (Monotherapy, Treatment-experienced) in United Kingdom (PO, Controlled release), before February 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top